non-Hodgkin's lymphoma

non-Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is part of the immune system and helps to fight infection and disease, as described by National Cancer Institute and American Cancer Society. It is a serious and potentially life-threatening condition that requires prompt medical attention, according to Centers for Disease Control and Prevention and World Health Organization. non-Hodgkin's lymphoma is named after Thomas Hodgkin, who first described a similar condition, Hodgkin's lymphoma, in the 19th century, and is distinct from Hodgkin's lymphoma in terms of its pathology and treatment, as noted by Mayo Clinic and Memorial Sloan Kettering Cancer Center. The condition has been studied extensively by researchers at Harvard University, Stanford University, and University of California, Los Angeles.

● Definition and Classification

non-Hodgkin's lymphoma is a type of lymphoma that arises from the lymphocytes, which are a type of white blood cell that plays a key role in the immune system, as explained by National Institute of Allergy and Infectious Diseases and European Organisation for Research and Treatment of Cancer. The condition is classified into several subtypes, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, according to World Health Organization and International Agency for Research on Cancer. These subtypes are characterized by distinct histological and molecular features, as described by American Society of Clinical Oncology and European Society for Medical Oncology. Researchers at University of Oxford, University of Cambridge, and Massachusetts Institute of Technology have made significant contributions to the understanding of non-Hodgkin's lymphoma.

● Causes and Risk Factors

The exact causes of non-Hodgkin's lymphoma are not fully understood, but several risk factors have been identified, including infection with Epstein-Barr virus, human immunodeficiency virus, and Helicobacter pylori, as noted by Centers for Disease Control and Prevention and National Institute of Allergy and Infectious Diseases. Other risk factors include immunodeficiency, autoimmune disorders, and exposure to chemicals such as pesticides and solvents, according to Environmental Protection Agency and Occupational Safety and Health Administration. Additionally, individuals with a family history of lymphoma or cancer are at increased risk of developing non-Hodgkin's lymphoma, as reported by American Cancer Society and National Cancer Institute. Studies conducted by researchers at Johns Hopkins University, University of Chicago, and Duke University have shed light on the potential causes and risk factors of non-Hodgkin's lymphoma.

● Symptoms and Diagnosis

The symptoms of non-Hodgkin's lymphoma can vary depending on the subtype and location of the tumor, but common symptoms include swollen lymph nodes, fever, night sweats, and weight loss, as described by Mayo Clinic and MedlinePlus. Diagnosis is typically made using a combination of imaging tests, such as computed tomography and magnetic resonance imaging, and biopsy, which involves removing a sample of tissue from the affected area, according to National Institute of Biomedical Imaging and Bioengineering and Society of Nuclear Medicine and Molecular Imaging. The tissue sample is then examined under a microscope to look for abnormal cells, as explained by American Society for Clinical Pathology and College of American Pathologists. Researchers at University of California, San Francisco, University of Pennsylvania, and Columbia University have developed new diagnostic techniques for non-Hodgkin's lymphoma.

● Types and Subtypes

There are several subtypes of non-Hodgkin's lymphoma, each with distinct characteristics and treatment options, as noted by World Health Organization and International Agency for Research on Cancer. Some of the most common subtypes include diffuse large B-cell lymphoma, which is the most common subtype, accounting for approximately 30% of all non-Hodgkin's lymphoma cases, according to National Cancer Institute and American Cancer Society. Other subtypes include follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma, which is a rare and aggressive subtype, as described by St. Jude Children's Research Hospital and Children's Oncology Group. Researchers at University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute have made significant contributions to the understanding of non-Hodgkin's lymphoma subtypes.

● Treatment and Management

Treatment for non-Hodgkin's lymphoma depends on the subtype, stage, and overall health of the individual, as explained by National Comprehensive Cancer Network and European Society for Medical Oncology. Common treatment options include chemotherapy, radiation therapy, and immunotherapy, which uses the body's own immune system to fight cancer, according to Food and Drug Administration and European Medicines Agency. In some cases, stem cell transplantation may be necessary, as noted by National Marrow Donor Program and European Group for Blood and Marrow Transplantation. Researchers at University of Washington, University of Michigan, and Yale University have developed new treatment strategies for non-Hodgkin's lymphoma.

● Prognosis and Outlook

The prognosis and outlook for non-Hodgkin's lymphoma vary depending on the subtype, stage, and response to treatment, as described by American Cancer Society and National Cancer Institute. In general, the 5-year survival rate for non-Hodgkin's lymphoma is approximately 70%, according to Surveillance, Epidemiology, and End Results Program and National Center for Health Statistics. However, some subtypes, such as diffuse large B-cell lymphoma, have a more favorable prognosis, with a 5-year survival rate of approximately 60%, as reported by National Institute of Health and European Organisation for Research and Treatment of Cancer. Researchers at Stanford University, Harvard University, and University of California, Los Angeles have made significant contributions to the understanding of non-Hodgkin's lymphoma prognosis and outlook.

● Epidemiology

non-Hodgkin's lymphoma is a relatively common type of cancer, accounting for approximately 4% of all new cancer cases in the United States, according to National Cancer Institute and Centers for Disease Control and Prevention. The incidence of non-Hodgkin's lymphoma has been increasing over the past few decades, with approximately 72,000 new cases diagnosed in 2020, as reported by American Cancer Society and National Institute of Health. The condition is more common in older adults, with a median age at diagnosis of 67 years, according to National Center for Health Statistics and Surveillance, Epidemiology, and End Results Program. Researchers at University of Oxford, University of Cambridge, and Massachusetts Institute of Technology have studied the epidemiology of non-Hodgkin's lymphoma. Category:Cancer